# A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

> **NCT05749042** · PHASE2 · UNKNOWN · sponsor: **Xin-Hua Xu** · enrollment: 70 (estimated)

## Conditions studied

- Oral Cavity Squamous Cell Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05749042
- **Lead sponsor:** Xin-Hua Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-18
- **Primary completion:** 2025-01-18
- **Final completion:** 2025-01-18
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05749042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05749042, "A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05749042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*